卡瑞利珠单抗联合子宫动脉介入栓塞化疗对复发或转移性宫颈癌疗效及血清因子表达的影响  

Effect of carrelizumab combined with uterine artery interventional chemoembolization on the efficacy and serum factor expression of recurrent or metastatic cervical cancer

作　　者：许立国[1] 林亚超 黄文浩[1] 冯广森[1] XU Liguo;LIN Yachao;HUANG Wenhao;FENG Guangsen(Department of Interventional Radiology,the Second Affiliated Hospital of Zhengzhou,Zhengzhou,Henan,China,450000)

机构地区：[1]郑州大学第二附属医院放射介入科,河南郑州450000

出　　处：《分子诊断与治疗杂志》2024年第11期2050-2054,共5页Journal of Molecular Diagnostics and Therapy

基　　金：河南省中青年医学健康创新项目(yxkc2020037)。

摘　　要：目的探讨卡瑞利珠单抗联合子宫动脉介入栓塞化疗对宫颈癌首次治疗后复发、转移患者的疗效及血清因子表达的影响。方法选取2020年1月至2023年1月在郑州大学第二附属医院接受治疗的88例复发/转移性宫颈癌病例进行研究,根据治疗方式分为对照组(n=41)与观察组(n=47),其中对照组采用子宫动脉介入栓塞化疗治疗,观察组在对照组的基础上联合卡瑞利珠单抗进行治疗。比较两组治疗后6个月近期疗效及不良反应发生情况;比较两组治疗前后肿瘤标志物[鳞状细胞癌抗原(SCC⁃Ag)、癌抗原125(CA⁃125)、癌胚抗原(CEA)]及T淋巴细胞亚群变化;检测外周血微小RNA(miR)⁃367、miR⁃383表达水平并进行比较。结果与对照组相比,观察组客观缓解率和疾病控制率均明显提高,差异有统计学意义(χ^(2)=4.756,4.342,P<0.05),观察组骨髓抑制及血小板减少的发生率较低,差异有统计学意义(χ^(2)=4.641,4.128,P<0.05)。与治疗前相比,两组SCC⁃Ag、CA⁃125、CEA含量降低,且观察组低于对照组,差异有统计学意义(t=15.668,9.641,10.787,P<0.05)。两组CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)比值降低,观察组CD4^(+)、CD4^(+)/CD8^(+)水平高于对照组,CD8^(+)水平低于对照组,差异有统计学意义(t=2.690,7.674,3.592,P<0.05)。两组血清miR⁃367、miR⁃383相对表达量升高,且观察组显著高于对照组,差异有统计学意义(t=7.372,9.273,P<0.05)。结论卡瑞利珠单抗联合子宫动脉介入栓塞化疗可减轻宫颈癌首次治疗后复发或转移患者的免疫抑制,并促进miR⁃367、miR⁃383的表达,抗肿瘤疗效显著。Objective To investigate the effect of carrelizumab combined with uterine artery interventional chemoembolization on the efficacy and serum factor expression of recurrent or metastatic cervical cancer.Methods A retrospective analysis was conducted on 88 patients with recurrent/metastatic cervical can⁃cer admitted to the Second Affiliated Hospital of Zhengzhou University from January 2020 to January 2023.The patients were divided into two groups:a control group(n=41)and an observation group(n=47)based on their treatment method.The control group received uterine artery interventional chemoembolization,while the observation group received carrelizumab in addition to the control group's treatment.Short⁃term efficacy and adverse reactions were compared between the two groups 6 months after treatment.Changes in tumor markers:squamous cell carcinoma antigen(SCC⁃Ag),cancer antigen 125(CA⁃125),carcinoembryonic antigen(CEA),and T lymphocyte subsets before and after treatment were compared between the two groups.The expression levels of miR⁃367 and miR⁃383 in peripheral blood were detected and compared between the two groups.Results After 6 months of follow⁃up,the objective remission rate and disease control rate in the observation group were significantly improved compared to the control group(χ^(2)=4.756,4.342,P<0.05).The incidence of bone marrow suppression and thrombocytopenia in the observation group was lower,with a statistically significant difference(χ^(2)=4.641,4.128,P<0.05).The levels of SCC⁃Ag,CA⁃125,and CEA in both groups decreased compared to before treatment,with the observation group showing lower levels than the control group,and these differences were statistically significant(t=15.668,9.641,10.787,P<0.05).CD4^(+),CD8^(+),and CD4^(+)/CD8^(+)levels in both groups were significantly reduced,but CD4^(+)and CD4^(+)/CD8^(+)were signifi⁃cantly increased in the observation group compared to the control group,while CD8^(+)was significantly reduced(t=2.690,7.674,3.592,P<0.05).The levels of miR�

关 键 词：卡瑞利珠单抗 子宫动脉介入栓塞化疗 复发/转移性宫颈癌 miR⁃383 miR⁃367 

分 类 号：R737.33[医药卫生—肿瘤]